全文获取类型
收费全文 | 56179篇 |
免费 | 4636篇 |
国内免费 | 1919篇 |
专业分类
耳鼻咽喉 | 371篇 |
儿科学 | 1273篇 |
妇产科学 | 976篇 |
基础医学 | 6971篇 |
口腔科学 | 1214篇 |
临床医学 | 4769篇 |
内科学 | 8330篇 |
皮肤病学 | 1032篇 |
神经病学 | 3330篇 |
特种医学 | 1206篇 |
外国民族医学 | 8篇 |
外科学 | 3926篇 |
综合类 | 8023篇 |
现状与发展 | 3篇 |
预防医学 | 5654篇 |
眼科学 | 1272篇 |
药学 | 7702篇 |
14篇 | |
中国医学 | 3254篇 |
肿瘤学 | 3406篇 |
出版年
2024年 | 162篇 |
2023年 | 761篇 |
2022年 | 1719篇 |
2021年 | 2231篇 |
2020年 | 1817篇 |
2019年 | 1910篇 |
2018年 | 1886篇 |
2017年 | 1876篇 |
2016年 | 2017篇 |
2015年 | 2043篇 |
2014年 | 3482篇 |
2013年 | 4047篇 |
2012年 | 3455篇 |
2011年 | 3680篇 |
2010年 | 2973篇 |
2009年 | 2784篇 |
2008年 | 2678篇 |
2007年 | 2369篇 |
2006年 | 2160篇 |
2005年 | 1957篇 |
2004年 | 1771篇 |
2003年 | 1513篇 |
2002年 | 1281篇 |
2001年 | 1162篇 |
2000年 | 966篇 |
1999年 | 812篇 |
1998年 | 693篇 |
1997年 | 654篇 |
1996年 | 551篇 |
1995年 | 526篇 |
1994年 | 511篇 |
1993年 | 406篇 |
1992年 | 347篇 |
1991年 | 315篇 |
1990年 | 343篇 |
1989年 | 290篇 |
1988年 | 253篇 |
1987年 | 244篇 |
1986年 | 203篇 |
1985年 | 429篇 |
1984年 | 516篇 |
1983年 | 359篇 |
1982年 | 342篇 |
1981年 | 309篇 |
1980年 | 281篇 |
1979年 | 259篇 |
1978年 | 203篇 |
1977年 | 170篇 |
1976年 | 185篇 |
1975年 | 152篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
12.
Family-centered care (FCC) for sick newborns is emerging as a paradigmatic shift in the practice of facility-based newborn care. It seeks to transforming a provider-centered model into a client-centered one and thus build a new therapeutic alliance. FCC is the cornerstone of continuum of care, imparting caregiving competencies to parents/caregivers both within institutions as well as after the discharge. This has potential gains for the newborn, family members, and facility-level staff. The initial model piloted in tertiary-care settings is now undergoing translation at five sites across the country; the outcomes are keenly awaited. 相似文献
13.
14.
《Vaccine》2021,39(45):6601-6613
AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc) in clinical development for the induction and augmentation of neutralizing IgG titers against SARS-CoV-2 viral infection to address the COVID-19 pandemic. The Fc moiety is designed to enhance immunogenicity by increasing uptake via Fc-receptors (FcγR) on Ag-presenting cells (APCs) and prolonging exposure due to neonatal Fc receptor (FcRn) recycling. AKS-452 induced approximately 20-fold greater neutralizing IgG titers in mice relative to those induced by SP/RBD without the Fc moiety and induced comparable long-term neutralizing titers with a single dose vs. two doses. To further enhance immunogenicity, AKS-452 was evaluated in formulations containing a panel of adjuvants in which the water-in-oil adjuvant, Montanide™ ISA 720, enhanced neutralizing IgG titers by approximately 7-fold after one and two doses in mice, including the neutralization of live SARS-CoV-2 virus infection of VERO-E6 cells. Furthermore, ISA 720-adjuvanted AKS-452 was immunogenic in rabbits and non-human primates (NHPs) and protected from infection and clinical symptoms with live SARS-CoV-2 virus in NHPs (USA-WA1/2020 viral strain) and the K18 human ACE2-trangenic (K18-huACE2-Tg) mouse (South African B.1.351 viral variant). These preclinical studies support the initiation of Phase I clinical studies with adjuvanted AKS-452 with the expectation that this room-temperature stable, Fc-fusion subunit vaccine can be rapidly and inexpensively manufactured to provide billions of doses per year especially in regions where the cold-chain is difficult to maintain. 相似文献
15.
《Drug discovery today》2022,27(6):1733-1742
Compounds that exhibit assay interference or undesirable mechanisms of bioactivity are routinely encountered in assays at various stages of drug discovery. We observed that assays for the investigation of thiol-reactive and redox-active compounds have not been collected in a comprehensive review. Here, we review these assays and subject them to experimental optimization to improve their reliability. We demonstrate the usefulness of our assay cascade by assaying a library of bioactive compounds, chemical probes, and a set of approved drugs. These high-throughput assays should complement the array of wet-lab and in silico assays during the initial stages of hit discovery campaigns to pursue only hit compounds with tractable mechanisms of action. 相似文献
16.
Wei Zhang Zheng Li Feng-Qing Xu Ya-Shuo Ren Shuang-Wang Xu Tong-Sheng Wang 《Journal of Asian natural products research》2019,21(5):426-434
Two new 11-methoxyl substituted triterpenoids, named as mimengosides J (1) and K (2), along with seven known compounds, were isolated from the fruits of Buddleja lindleyana. Their structures were elucidated on the basis of spectroscopic analysis. In addition, the new ones were evaluated for protective effects against damage of SH-SY5Y cells induced by 1-methyl-4-phenylpyridinium ion (MPP+) and the results indicated that those may be one of the candidate compositions of Buddleja lindleyana for the treatment of neurodegenerative disease.
17.
18.
Mayuko Kinoshita Haruka Kaneko Lizu Liu Masashi Nagao Ryo Sadatsuki 《Modern rheumatology / the Japan Rheumatism Association》2019,29(1):157-164
Objectives: To examine the factors associated with increase in lumbar spine bone mineral density (LS-BMD) by bisphosphonates (BPs) with active vitamin D analog (aVD).Methods: Two independent postmenopausal osteoporotic patients treated by BPs with aVD for 24 months (Study 1: n?=?93, Study 2: n?=?99) were retrospectively analyzed.Results: In Study 1, LS-BMD of the patients significantly increased for 24 m (5.4%, p?.001). A multiple regression analysis among baseline characteristics revealed that serum calcium (sCa: 8.5–10.5?mg/dL) was associated with an increased LS-BMD by treatment (r2: 0.088, p?=?.02). While average sCa of the patients was 9.2?mg/dL before treatment, it increased time-dependently to 9.6?mg/dL for 24 m by treatment. As each patient had their LS-BMD five times during the study, there were four instances of %LS-BMD in each patient, resulting in 372 instances of %LS-BMD in Study 1. The smallest Akaike’s information criterion value for the most appropriate cut-off levels of sCa for %LS-BMD by treatment every 6 m was 9.3?mg/dL. The %LS-BMD by treatment for 6 m during 24 m period in patients with sCa ≥9.3?mg/dL (1.5%) was significantly higher than that in patients with sCa <9.3?mg/dL (0.8%, p?=?.038). The results of Study 2 were similar to those of Study 1, confirming the phenomena observed.Conclusion: sCa was associated with an increased LS-BMD by BPs with aVD. 相似文献
19.
Takahiro Namiki Chika Takano Ryoji Aoki Quang Duy Trinh Ichiro Morioka Satoshi Hayakawa 《Congenital anomalies》2022,62(1):38-41
Congenital rubella syndrome (CRS) results from maternal rubella virus infection in early pregnancy. Abnormal neuroimaging findings have been analyzed in a small number of CRS patients in the past; however, their clinical significance has been poorly addressed. Therefore, we have investigated the neuroimaging findings of 31 patients with CRS from previous studies. The most common finding was parenchymal calcification, which was observed in 18 of 31 patients (58.1%). A multivariable logistic regression model showed that it was associated with psychomotor or mental retardation (p = 0.018), suggesting that parenchymal calcification in CRS could be a prognostic factor. 相似文献
20.
目的探讨喉癌患者血小板表面血小板膜糖蛋白Ⅱb/Ⅲa纤维蛋白原受体(PAC-1)、血小板P-选择素(CD62P)阳性表达率以及与患者临床病理特征和复发的关系。方法选取2014年1月~2015年12月间在我院耳鼻喉科手术治疗的116例喉癌患者,随访≥2年,并选取同期在我院体检的健康人群60例为对照组,采用流式细胞仪检测法检测外周血PAC-1和CD62P阳性率,并分析与临床病理特征、复发的关系。结果喉癌患者PAC-1和CD62P阳性表达率分别为(17.82±1.76)%和(22.87±3.13)%,明显高于健康人群(P<0.05);而且在喉癌患者PAC-1表达和CD62P表达呈正相关性(r=0.238,P<0.05)。T3-T4分期或N2-N3分期患者PAC-1和CD62P阳性表达率高于T1-T2分期或N0-N1分期患者(P<0.05)。另外远处转移组PAC-1和CD62P阳性表达率高于未发生转移组(P<0.05);随访期间有24例患者复发,复发率为20.69%。复发喉癌患者PAC-1、CD62P阳性表达率分别为(17.02±0.85)%和(21.84±1.17)%,明显高于未复发的喉癌患者(P<0.05)。经Logistics回归分析,PAC-1和CD62P是喉癌患者复发的独立危险因素(P<0.05)。结论PAC-1和CD62P阳性表达率与喉癌患者T分期、淋巴结转移和远处转移密切相关,同时可作为喉癌局部复发、区域淋巴结转移、远处转移的预测指标。 相似文献